Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Ruxolitinib
État du projet:
Terminé
Domaine thérapeutique:
Myelofibrosis
Fabricant:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Jakavi
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0012-000
Indicateur de rendement:
S. O. – Mesures de rendement prédictives
Strength:
5mg, 15mg, and 20mg
Tumour Type:
Other
Indications:
Myelofibrosis
Funding Request:
For the treatment of patients with myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.
Review Status:
Complete
Date NOC Issued:
Sponsor:
Novartis Pharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016